Sugi Predict

Sugi Predict / Compounds / SCHEMBL4500667

SCHEMBL4500667

SCHEMBL4500667

CCCc1ccc(Oc2nc(Nc3ccc(N4CCN(C)C(C)C4)c(F)c3)ncc2C(=O)Nc2c(C)cccc2C)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIK1 P57059 2/20 0.51
▸ SIK2 Q9H0K1 2/20 0.51
▸ SIK3 Q9Y2K2 2/20 0.51
▸ LCK P06239 3/20 0.48
▸ BTK Q06187 2/20 0.48
▸ JAK3 P52333 2/20 0.48
▸ TNK2 Q07912 1/20 0.48
▸ PAK1 Q13153 4/20 0.43
▸ EGFR P00533 4/20 0.43
▸ CSF1R P07333 4/20 0.43
▸ FLT3 P36888 1/20 0.40
▸ KDR P35968 2/20 0.39
▸ MAPK14 Q16539 2/20 0.39
▸ SRC P12931 2/20 0.39
▸ TEK Q02763 1/20 0.38
▸ BRD4 O60885 2/20 0.38
▸ JAK1 P23458 2/20 0.38
▸ CDK1 P06493 1/20 0.38
▸ CDK4 P11802 1/20 0.38
▸ CCNB1 P14635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4505967 0.94 SIK1 (0.48) SIK1SIK2SIK3LCKBTK
SCHEMBL5686230 0.93 SIK1 (0.48) SIK1SIK2SIK3LCKBTK
SCHEMBL4502009 0.93 SIK1 (0.48) SIK1SIK2SIK3LCKBTK
SCHEMBL4497629 0.92 SIK1 (0.58) SIK1SIK2SIK3LCKBTK
SCHEMBL4485369 0.91 SIK1 (0.51) SIK1SIK2SIK3LCKBTK
SCHEMBL4489983 0.91 SIK1 (0.48) SIK1SIK2SIK3LCKBTK
SCHEMBL4497776 0.91 SIK1 (0.48) SIK1SIK2SIK3LCKBTK
SCHEMBL4508543 0.91 SIK1 (0.46) SIK1SIK2SIK3LCKBTK
SCHEMBL4497433 0.91 SIK1 (0.47) SIK1SIK2SIK3LCKBTK
SCHEMBL4497147 0.91 SIK1 (0.48) SIK1SIK2SIK3LCKBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648464-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AMGEN INC. (US) 2006-04-26 — — EP claimed
US-20050209221-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2005-09-22 — — US claimed
WO-2005009443-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES AMGEN INC. (US) 2005-02-03 — — WO claimed
US-7504396-B2 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2009-03-17 — — US disclosed
EP-1648464-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AMGEN INC. (US) 2006-04-26 — — EP disclosed
US-20050209221-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2005-09-22 — — US disclosed
WO-2005009443-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES AMGEN INC. (US) 2005-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209221-A1 Substituted heterocyclic compounds and methods of use ICOS, CD4, HLA-DRB1 SIK1 1588/4885SIK2 1559/4885SIK3 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.